Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 3479.

https://doi.org/10.1182/blood-2023-182430

Published: 2023

Journal Articles

Long Term Disease Free Survival and Survival of Patients with Relapsed Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplantation

Sabree Abedrabo, Tulio E. Rodriguez, Leonard M. Klein, Jacob Bitran

Blood (2023) 142 (Supplement 1): 7078.

https://doi.org/10.1182/blood-2023-174684

Published: 2023

Journal Articles

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen

Patrick Hagen, MD, Anita D'Souza, MDMS, Parameswaran Hari, MBBS, MD, Omar Davila, Mei-Jie Zhang, David H. Vesole, MD PhD, Scott E. Smith, MD PhD, Tulio E Rodriguez, MD, Patrick J. Stiff, MD

Blood (2019) 134 (Supplement_1): 2023.

https://doi.org/10.1182/blood-2019-124188

Published: 2019

Journal Articles

Risk Factors for the Development of Cardiac Arrhythmias during Hematopoietic Stem Cell Transplantation

Christopher Kapolas, PharmD, Jane Kosirog-Glowacki, PharmD, Kathryn L Barney, NP, Linda Advincula, NP, Leonard M. Klein, MD, Jacob D. Bitran, MD, Shams Bufalino, Tulio E Rodriguez, MD

Blood (2018) 132 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2018-99-120189

Published: 2018

Journal Articles

Infliximab and Low Dose Alemtuzumab in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Daniel Kobrinski, DO, Tulio E. Rodriguez, MD, Scott E. Smith, MD PhD, Stephanie B. Tsai, MD MA, Zeina Al-Mansour, MD, Mala Parthasarathy, MS, Patrick J. Stiff, MD

Blood (2016) 128 (22): 5795.

https://doi.org/10.1182/blood.V128.22.5795.5795

Published: 2016

Journal Articles

Early Post-Transplantation Tacrolimus Levels Correlate with Acute Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation from Related and Unrelated Donors

Patrick A Hagen, MD MPH, Daniel Kobrinski, DO, Zeina Al-Mansour, MD, Stephanie B. Tsai, MD MA, Mala Parthasarathy, MS, Stephanie Kliethermes, PhD, Tulio E. Rodriguez, MD, Scott E. Smith, MD PhD, Patrick J. Stiff, MD

Blood (2016) 128 (22): 3429.

https://doi.org/10.1182/blood.V128.22.3429.3429

Published: 2016

Journal Articles

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial

Blood (2015) 126 (23): 737.

https://doi.org/10.1182/blood.V126.23.737.737

Published: 2015

Journal Articles

High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM)

Danielle Sterrenberg, MD, Patrick J Stiff, MD, Mala Parthasarathy, MS, Aileen Go, MD, Scott E. Smith, MD, PhD, Tulio E. Rodriguez, MD

Blood (2013) 122 (21): 3376.

https://doi.org/10.1182/blood.V122.21.3376.3376

Published: 2013

Journal Articles

Myeloablative Conditioning With Intravenous Busulfan and Pentostatin (Bu/Pent) Vs. Total Body Irradiation and Cyclophosphamide (TBI/Cy) For Elderly Patients With Acute Myeloid Leukemia Or Myelodysplasia

Shikha Jain, MD, Patrick J Stiff, MD, Scott E. Smith, MD, PhD, Aileen Go, MD, Mala Parthasarathy, MS, Tulio E. Rodriguez, MD

Blood (2013) 122 (21): 5450.

https://doi.org/10.1182/blood.V122.21.5450.5450

Published: 2013

Journal Articles

Transplant Strategies For The Initial Management Of Mantle Cell Lymphoma: A Single Institution Analysis

Camille Adeimy, MD, Daniel Kobrinski, DO, Patrick J Stiff, MD, Tulio E. Rodriguez, MD, Aileen Go, MD, Mala Parthasarathy, MS, Scott E. Smith, MD, PhD

Blood (2013) 122 (21): 5533.

https://doi.org/10.1182/blood.V122.21.5533.5533

Published: 2013

Journal Articles

Busulfan / Melphalan / Bortezomib (Bu-Mel-Vel) Vs. High Dose Melphalan As Conditioning Regimen For Autologous Hematopoietic Cell Transplantation In Multiple Myeloma (MM)

Tulio E. Rodriguez, MD, Parameswaran Hari, MD, MS, Patrick J Stiff, MD, Xiaobo Zhong, MS, Danielle Sterrenberg, MD, David H. Vesole, MD, PhD

Blood (2013) 122 (21): 3357.

https://doi.org/10.1182/blood.V122.21.3357.3357

Published: 2013

Journal Articles

Prognostic Value Of Disease Status At Time Of Allogeneic Transplant For Relapsed Non-Hodgkin’s Lymphoma

Shams Bakhos, MD, Brubaker L Aleah, PhD, Mala Parthasarathy, MS, Aileen Go, MD, Tulio E. Rodriguez, MD, Patrick J Stiff, MD, Scott E. Smith, MD, PhD

Blood (2013) 122 (21): 3412.

https://doi.org/10.1182/blood.V122.21.3412.3412

Published: 2013

Journal Articles

Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation.

Blood (2012) 120 (21): 3080.

https://doi.org/10.1182/blood.V120.21.3080.3080

Published: 2012

Journal Articles

Long Term Follow-up of Allogeneic Transplantation Using BEAM Chemotherapy for Patients with Hodgkin's Lymphoma Who Relapse After Autologous Transplantation: Importance of Minimal Residual Disease At Transplant.

Urszula A Sobol, MD, Tulio E. Rodriguez, MD, Scott E. Smith, MD, PhD, Aileen Go, MD, Ross Vimr, MD, Mala Parthasarathy, MS, Rong Guo, MS, Patrick Stiff, MD

Blood (2012) 120 (21): 3131.

https://doi.org/10.1182/blood.V120.21.3131.3131

Published: 2012

Journal Articles

Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America

Blood (2012) 120 (21): 813.

https://doi.org/10.1182/blood.V120.21.813.813

Published: 2012

Journal Articles

Correlation of Ethnicity, Socioeconomic Status, and Co-Morbidity with Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.

Brian Hess, MD, Matthew Siegel, MD, Tulio E. Rodriguez, MD, Shams Bakhos, MD, Maria Theodorou, Michael Tallarico, MD, Scott E. Smith, MD, PhD, Aileen Go, MD, Patrick Stiff, MD

Blood (2012) 120 (21): 3102.

https://doi.org/10.1182/blood.V120.21.3102.3102

Published: 2012

Journal Articles

Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation

Cesar O. Freytes, MD, Juan J. Toro, MD, MSci, Rosa F. Yeh, PharmD, Edward A. Stadtmauer, MD, Voravit Ratanatharathorn, MD, Gorgun Akpek, MD, MHS, Entezam Sahovic, MD, Guido J. Tricot, MD, PhD, Paul J. Shaughnessy, MD, Darrell J. White, MD, Tulio E. Rodriguez, MD, Scott R. Solomon, MD, Louie H. Yu, BS, Shiva Patil, PhD, Yiping Sun, PhD, Elizabeth Armstrong, MS, Agnes Elekes, MD, Kazunobu Kato, MD, PhD, Donna E. Reece, MD, FRCPC

Blood (2011) 118 (21): 4509.

https://doi.org/10.1182/blood.V118.21.4509.4509

Published: 2011

Journal Articles

High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)

Tulio E. Rodriguez, M.D., Patrick J. Stiff, MD, Scott E. Smith, MD, PhD, FACP, Jonathan L. Kaufman, MD, Mary Lee, RN, Mala Parthasarathy, MS, Zachary M. Earley, Sagar Lonial, MD, David H. Vesole, MD, PhD

Blood (2010) 116 (21): 1355.

https://doi.org/10.1182/blood.V116.21.1355.1355

Published: 2010

Journal Articles

Effectiveness of Reduced Toxicity Conditioning Regimen with Intravenous Busulfan Plus Pentostatin (BUPENT) in Patients Older Than 50 Years with Advanced Hematologic Malignancies.

Tulio E. Rodriguez, MD, Mala Parthasarathy, MS, Scott E. Smith, MD, PhD, David H. Vesole, MD, PhD, Zachary M. Earley, Aaron T. Gerds, MD, Amir A. Toor, MD, Patrick J. Stiff, MD

Blood (2009) 114 (22): 3331.

https://doi.org/10.1182/blood.V114.22.3331.3331

Published: 2009

Journal Articles

Refractory Thrombocytopenia Due to Allo-Immune Anti-CD36 Complicating Unrelated Donor Bone Marrow Transplant in a CD36-Negative Recipient.

William R. Broderick, MD, Amir A. Toor, MD, Brian R. Curtis, MS, Tulio E. Rodriguez, MD, Scott E. Smith, MD, PhD, Patrick J. Stiff, MD, Phillip J. DeChristopher, MD, PhD

Blood (2007) 110 (11): 4951.

https://doi.org/10.1182/blood.V110.11.4951.4951

Published: 2007

NARROW

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Long Term Disease Free Survival and Survival of Patients with Relapsed Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplantation

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen

Risk Factors for the Development of Cardiac Arrhythmias during Hematopoietic Stem Cell Transplantation

Infliximab and Low Dose Alemtuzumab in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Early Post-Transplantation Tacrolimus Levels Correlate with Acute Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation from Related and Unrelated Donors

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial

High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM)

Myeloablative Conditioning With Intravenous Busulfan and Pentostatin (Bu/Pent) Vs. Total Body Irradiation and Cyclophosphamide (TBI/Cy) For Elderly Patients With Acute Myeloid Leukemia Or Myelodysplasia

Transplant Strategies For The Initial Management Of Mantle Cell Lymphoma: A Single Institution Analysis

Busulfan / Melphalan / Bortezomib (Bu-Mel-Vel) Vs. High Dose Melphalan As Conditioning Regimen For Autologous Hematopoietic Cell Transplantation In Multiple Myeloma (MM)

Prognostic Value Of Disease Status At Time Of Allogeneic Transplant For Relapsed Non-Hodgkin’s Lymphoma

Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation.

Long Term Follow-up of Allogeneic Transplantation Using BEAM Chemotherapy for Patients with Hodgkin's Lymphoma Who Relapse After Autologous Transplantation: Importance of Minimal Residual Disease At Transplant.

Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America

Correlation of Ethnicity, Socioeconomic Status, and Co-Morbidity with Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.

Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation

High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)

Effectiveness of Reduced Toxicity Conditioning Regimen with Intravenous Busulfan Plus Pentostatin (BUPENT) in Patients Older Than 50 Years with Advanced Hematologic Malignancies.

Refractory Thrombocytopenia Due to Allo-Immune Anti-CD36 Complicating Unrelated Donor Bone Marrow Transplant in a CD36-Negative Recipient.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only